Iyer Vidyashankara, Cayatte Corinne, Marshall Jason D, Sun Jenny, Schneider-Ohrum Kirsten, Maynard Sean K, Rajani Gaurav Manohar, Bennett Angie Snell, Remmele Richard L, Bishop Steve M, McCarthy Michael P, Muralidhara Bilikallahalli K
Biopharmaceutical Development, MedImmune, Gaithersburg, Maryland 20878.
Vaccine Platform Group, MedImmune, Gaithersburg, Maryland 20878.
J Pharm Sci. 2017 Jun;106(6):1490-1498. doi: 10.1016/j.xphs.2017.02.024. Epub 2017 Mar 1.
To generate potent vaccine responses, subunit protein antigens typically require coformulation with an adjuvant. Oil-in-water emulsions are among the most widely investigated adjuvants, based on their demonstrated ability to elicit robust antibody and cellular immune responses in the clinic. However, most emulsions cannot be readily frozen or lyophilized, on account of the risk of phase separation, and may have a deleterious effect on protein antigen stability when stored long term as a liquid coformulation. To circumvent this, current emulsion-formulated vaccines generally require a complex multivial presentation with obvious drawbacks, making a single-vial presentation for such products highly desirable. We describe the development of a stable, lyophilized squalene emulsion adjuvant through innovative formulation and process development approaches. On reconstitution, freeze-dried emulsion preparations were found to have a minimal increase in particle size of ∼20 nm and conferred immunogenicity in BALB/c mice similar in potency to freshly prepared emulsion coformulations in liquid form.
为了产生有效的疫苗反应,亚单位蛋白抗原通常需要与佐剂共同配制。水包油乳剂是研究最为广泛的佐剂之一,因为它们在临床上已被证明能够引发强烈的抗体和细胞免疫反应。然而,大多数乳剂由于存在相分离的风险,不易冷冻或冻干,并且以液体共同制剂形式长期储存时,可能会对蛋白质抗原的稳定性产生有害影响。为了规避这一问题,目前采用乳剂配制的疫苗通常需要复杂的多瓶包装,存在明显缺点,因此非常希望此类产品能够实现单瓶包装。我们通过创新的配方和工艺开发方法,描述了一种稳定的冻干角鲨烯乳剂佐剂的研发过程。复溶后发现,冻干乳剂制剂的粒径仅略有增加,约为20纳米,并且在BALB/c小鼠中赋予的免疫原性与新鲜制备的液体形式的乳剂共同制剂效力相似。